MLTX MoonLake Accounting Capitalization

Public company logo of MoonLake (MLTX)

MoonLake Immunotherapeutics (MLTX) revenues will be based on the market launch of advanced nanobodies (sonelokimab) targeting skin and joint inflammation. The company's strategy relies on successful trials of psoriasis drugs to capture a share of the immunology segment. The current metric is 0.43. The asset's price history on the GURU.Markets platform clearly demonstrates the market volatility of this biotechnology company.

MLTX MoonLake Corp Book Capitalization (04/28/2023 - 10/29/2026)

Metric breakdowns and analytics for MoonLake (MLTX)

- price and consensus price forecast:
Price MoonLake Corp|MLTX - Consensus Target
- market capitalization data:
Market Capitalization MoonLake Immunotherapeutics AG|MLTX - Total Company Value
- book capitalization data:
Share Book Value MoonLake Immunotherapeutics|MLTX - Book Capitalization|Market Value to Book Value moonlaketx.com|MLTX - Company Total Assets
- debt and liquidity data:
Total Debt to Capital MoonLake Immunotherapeutics|MLTX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital MoonLake Immunotherapeutics AG|MLTX - Company Debts|Debt to Book Value MoonLake Immunotherapeutics AG|MLTX - Company Long-Term Debts|Company Short-Term Debts MoonLake Immunotherapeutics
Fundamental valuation:MLTX - MoonLake Corp
Flagship merchandise of MoonLake Immunotherapeutics AG

Book value capitalization reflects the daily dynamics of net assets minus all liabilities, allowing investors to track real capital accumulation without gaps between quarterly reports. An analysis of the current book value capitalization of MoonLake Immunotherapeutics (MLTX) demonstrates the financial foundation for the development of psoriasis antibodies, where the growth of this metric confirms the availability of resources to bring innovative drugs to market.

Competitor analysis for MoonLake Immunotherapeutics

Ascendis (ASND) - Total Net Assets|Company Net Assets Madrigal Pharmaceuticals|CORT (corcept.com) - Accounting Capitalization|Company Book Value Rhythm Pharmaceuticals, Inc. RYTM|Net Asset Value Akero Therapeutics, Inc.|Metsera Corp (MTSR) - Book Capitalization|Accounting Value of Company Crinetics Corp (CRNX)|Book Capitalization NAMS (NewAmsterdam Pharma)|soleno.life - Book Capitalization|Company Book Value Amicus Therapeutics, Inc. (FOLD)|ETNB: Accounting Value of Company|AGIO (Agios Pharmaceuticals Inc) - Company Book Value|Structure Corp (GPCR) - Company Net Assets|MDXG (MiMedx Group, Inc.) - Book Capitalization|Book Capitalization rezolutebio.com (RZLT)|Lexicon Pharmaceuticals, Inc. (LXRX) - Company Net Assets|Accounting Value of Company MBX (MBX Biosciences, Inc.)|Altimmune Corp - Company Book Value|Company Net Assets Aardvark Pharma AARD|SGMT (Sagimet Biosciences) - Book Capitalization|bioagelabs.com (BIOA) - Total Stockholders' Equity|BMEA - Company Net Assets|Quince Therapeutics, Inc. (QNCX) - Total Net Assets|GUTS (Fractyl) - Book Capitalization|Book Capitalization vTv Therapeutics Inc|Book Capitalization Agape ATP Corporation (ATPC)|Company Book Value PLUR (pluri-biotech.com)|SYBX: Company Book Value|Lipocine Inc - Total Stockholders' Equity|MTNB - Company Book Value|SPRB - Company Book Value|Galecto, Inc. - Book Capitalization|CTCX (carmellrx.com) - Book Valuation of Business|LUMO: Company Book Value|Book Valuation of Business ONVO|Company Book Value RDUS (Radius Health)